OKYO Pharma Ltd
OKYO Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โFY2026
Revenue
Total sales reported in the income statement.
โ
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$8.9M
Free cash flow
Cash from operations minus capital spending.
โ$5.9M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
What OKYO Pharma Ltd does
No business description yet.
- Legal name
- OKYO Pharma Ltd
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 20-F ยท Jul 20, 2026
- Accession ยท CIK
- 0001493152-26-033847
0001849296
Revenue and margins
OKYO Pharma Ltd had โ of revenue in fiscal 2026.
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue โ
FY26
Revenue โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
FY26
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$1.5M
FY21
Net income โ$3.4M
FY22
Net income โ$5.4M
FY23
Net income โ$13.3M
FY24
Net income โ$16.8M
FY25
Net income โ$4.7M
FY26
Net income โ$8.9M
FY20
Diluted EPS โ
FY21
Diluted EPS โ$0.32
FY22
Diluted EPS โ$0.36
FY23
Diluted EPS โ$0.61
FY24
Diluted EPS โ$0.57
FY25
Diluted EPS โ$0.12
FY26
Diluted EPS โ$0.24
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ
Return on assets โ
FY21
Return on capital โ
Return on equity โ129.5%
Return on assets โ47.3%
FY22
Return on capital โ
Return on equity โ131.4%
Return on assets โ95.3%
FY23
Return on capital โ
Return on equity โ2,968.4%
Return on assets โ279.3%
FY24
Return on capital โ
Return on equity โ
Return on assets โ498.9%
FY25
Return on capital โ
Return on equity โ
Return on assets โ180.4%
FY26
Return on capital โ
Return on equity โ263.8%
Return on assets โ72.6%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$5.9M in fiscal 2026, โ of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ
FY21
Free cash flow โ$1.6M
FY22
Free cash flow โ$5.5M
FY23
Free cash flow โ$7.7M
FY24
Free cash flow โ
FY25
Free cash flow โ$1.8M
FY26
Free cash flow โ$5.9M
FY20
Cash from operations โ$1.2M
Capital spending โ
FY21
Cash from operations โ$1.6M
Capital spending $0.0M
FY22
Cash from operations โ$5.5M
Capital spending $0.0M
FY23
Cash from operations โ$7.7M
Capital spending $0.0M
FY24
Cash from operations โ$9.5M
Capital spending โ
FY25
Cash from operations โ$1.8M
Capital spending $0.0M
FY26
Cash from operations โ$5.9M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
OKYO Pharma Ltd returned โ to shareholders in fiscal 2026. The diluted share count rose 0.0%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
FY26
Dividends โ
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.60B
FY21
Diluted shares 0.67B
FY22
Diluted shares 0.98B
FY23
Diluted shares โ
FY24
Diluted shares โ
FY25
Diluted shares โ
FY26
Diluted shares โ
Balance sheet
Cash, debt and the ratios that show how comfortably OKYO Pharma Ltd can carry it.
FY20
Cash $0.2M
Debt โ
FY21
Cash $6.9M
Debt โ
FY22
Cash $2.7M
Debt โ
FY23
Cash $4.0M
Debt โ
FY24
Cash $0.8M
Debt โ
FY25
Cash $1.6M
Debt $2.7M
FY26
Cash $14.6M
Debt โ
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.7M | $4.0M | $0.8M | $1.6M | $14.6M |
| Debt incl. finance leases | โ | โ | โ | $2.7M | โ |
| Current ratio | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Quick ratio | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Total assets | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M |
| Total liabilities | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M |
| Shareholders' equity | $2.9M | โ$2.1M | โ$5.9M | โ$5.5M | $12.3M |
| Net debt (โ = net cash) | โ | โ | โ | $1.1M | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 4 | โ / 6 | โ / 5 | โ / 5 | โ / 5 | โ / 5 |
| Accruals ratio | โ | โ24.7% | 0.7% | โ117.3% | โ217.5% | โ111.0% | โ24.4% |
| Altman Z'' | โ | โ | โ | โ | โ | โ | โ |
7 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | $0.5M | $0.3M | $1.6M | $6.3M | $8.2M | $2.3M | $1.8M |
| Interest expense | $0.0M | $0.0M | โ | $0.1M | $1.1M | $0.9M | $0.5M |
| Pretax income | โ$1.6M | โ$3.4M | โ$6.2M | โ$13.3M | โ$16.8M | โ$8.0M | โ$8.9M |
| Income tax | $0.1M | $0.0M | $0.8M | $0.0M | โ$0.0M | $3.3M | โ$0.0M |
| Net income | โ$1.5M | โ$3.4M | โ$5.4M | โ$13.3M | โ$16.8M | โ$4.7M | โ$8.9M |
| Diluted EPS | โ | โ$0.32 | โ$0.36 | โ$0.61 | โ$0.57 | โ$0.12 | โ$0.24 |
| Diluted shares | 0.60B | 0.67B | 0.98B | โ | โ | โ | โ |
| Cash flow | |||||||
| Cash from operations | โ$1.2M | โ$1.6M | โ$5.5M | โ$7.7M | โ$9.5M | โ$1.8M | โ$5.9M |
| Capital expenditure | โ | $0.0M | $0.0M | $0.0M | โ | $0.0M | $0.0M |
| Free cash flow | โ | โ$1.6M | โ$5.5M | โ$7.7M | โ | โ$1.8M | โ$5.9M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.0M | $0.6M | $1.7M | $1.3M | $1.1M | $0.7M | $1.6M |
| Balance sheet | |||||||
| Cash and short-term investments | $0.2M | $6.9M | $2.7M | $4.0M | $0.8M | $1.6M | $14.6M |
| Total debt | โ | โ | โ | โ | โ | $2.7M | โ |
| Current assets | โ | $7.0M | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M |
| Current liabilities | โ | $1.7M | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M |
| Property and equipment, net | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | โ | $7.1M | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M |
| Total liabilities | โ | $1.8M | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M |
| Shareholders' equity | โ$0.1M | $5.3M | $2.9M | โ$2.1M | โ$5.9M | โ$5.5M | $12.3M |
| Returns | |||||||
| Return on equity | โ | โ129.5% | โ131.4% | โ2,968.4% | โ | โ | โ263.8% |
| Return on assets | โ | โ47.3% | โ95.3% | โ279.3% | โ498.9% | โ180.4% | โ72.6% |
| Return on tangible equity | โ | โ63.0% | โ184.3% | โ | โ | โ | โ72.6% |
| Growth | |||||||
| Share count change | โ | 13.0% | 45.5% | โ | โ | โ | โ |
| Financial health | |||||||
| Current ratio | โ | 4.1x | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Quick ratio | โ | 4.1x | 3.2x | 0.7x | 0.2x | 0.4x | 2.4x |
| Quality scores | |||||||
| Accruals ratio | โ | โ24.7% | 0.7% | โ117.3% | โ217.5% | โ111.0% | โ24.4% |
Source: SEC EDGAR XBRL filings (CIK 0001849296). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only โ not investment advice. Check the original filings before relying on any figure.